# Patient With Advanced Aggressive B2 Thymoma Achieved Positive Outcomes Post CAP‐Endostar Combination Therapy

**Authors:** Min Zhang, Jingjing Zhang, Kelei Zhao, Xiaohan Yuan, Jinghang Zhang, Yanting Liu, Ping Lu

PMC · DOI: 10.1111/crj.70081 · 2025-06-22

## TL;DR

A patient with advanced thymoma showed significant improvement and long-term stability after receiving CAP-Endostar combination therapy.

## Contribution

This case report demonstrates the effectiveness of CAP-Endostar therapy in treating advanced invasive thymoma.

## Key findings

- Tumor size decreased significantly from 72.43 to 24 mm after six cycles of chemotherapy and radiotherapy.
- The patient remained in partial response with no recurrence or metastasis after 50 months of follow-up.

## Abstract

This case report features a patient with an invasive thymoma. The patient presented with an anterior mediastinal mass that invaded the left brachiocephalic trunk vein, resulting in the formation of a carcinoma thrombus in the right atrium, superior vena cava, left brachiocephalic trunk vein, and left internal jugular vein (Masaoka stage IV). No indication for surgery was assessed by surgical consultation. After six cycles of chemotherapy and chest radiotherapy, the tumor size decreased from 72.43 to 24 mm, showing a significant improvement in patient efficacy. After a follow‐up of 50 months, the patient remained well, without local recurrence or distal metastasis, and maintained a partial response (PR).

At the 50 months of follow‐up, the patient remained in a stable condition without evidence of local recurrence or distal metastases.

## Linked entities

- **Diseases:** thymoma (MONDO:0006456)

## Full-text entities

- **Diseases:** CAP (OMIM:115650), Thymoma (MESH:D013945), metastasis (MESH:D009362), tumor (MESH:D009369), carcinoma thrombus (MESH:D013927)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12182910/full.md

---
Source: https://tomesphere.com/paper/PMC12182910